🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07316101
Recruiting Not applicable

Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery

NCT07316101 · tracked via the Priya Life Science China tracker
Sponsor
West China Hospital
Phase
Not applicable
Started
2026-03-01
Last updated
2026-06-30

Condition(s) studied

Pituitary AdenomaCraniopharyngioma

Investigational drug(s) / intervention(s)

Anti-fog suction device-a 4 Fr multi-channel silicone catheter

Anti-fog suction device-a 4 Fr multi-channel silicone catheter: A single-use, sterile "anti-fog suction device" (a 4 Fr multi-channel silicone catheter) is introduced through the same nostril alongside the endoscope after induction of anaesthesia. The built-in micro-balloon is inflated with 1 ml air to anchor the tip in the posterior choana. Low-flow (2 L min-¹), filtered, room-temperature air is delivered through the central lumen, creating a gentle laminar stream that passes across the lens, continuously removing warm humid air and preventing condensation. Two side ports provide continuous low-pressure (-5 cmH₂O) suction of any blood or fluid, keeping the surgical field dry. The device remains in place for the entire operation and is removed before nasal packing. No extra incisions or sutures are required.

Study summary

The goal of this clinical trial is to learn if the anti-fog suction device works to keep the surgical view clear during endoscopic nose-to-pituitary operations and whether it lowers the chance of brain-fluid infection. It will also learn about the safety of the device.

The main questions it aims to answer are:

* Does the device reduce the total time the surgeon has to stop because the lens fogs up?
* What medical problems (such as nose-bleed, tube blockage, or infection) do participants have when the device is used?

Researchers will compare the anti-fog device to the usual "water-squirt" method to see if the device works better.

Participants will:

* Have either the device or the usual water method applied during their planned pituitary surgery
* Stay in the hospital for the normal recovery period (about 3-5 days) and return for a routine check-up around day 7
* Allow the study team to record operating times, any fog-related pauses, and results of blood or spinal-fluid tests taken before and after surgery

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-75 years * Pre-operative MRI/CT diagnosis of pituitary adenoma or craniopharyngioma ≤ \*3 cm without extensive skull-base invasion * Scheduled for elective endoscopic endonasal transsphenoidal resection * ASA physical status I-III * Able and willing to give written informed consent and comply with follow-up Exclusion Criteria: * Severe nasal anatomical deformity, polyps, or prior nasal surgery preventing device placement * Active nasal or systemic infection (WBC \> 10 × 10⁹/L, CRP ≥ 10 mg/L) * Known intracranial infection or ongoing CSF leak * Coagulopathy (PT \> 14 s or APTT \> 45 s) or anticoagulation that cannot be stopped ≥ 7 days * Allergy to silicone or medical-grade plastics * Planned combined transcranial or transorbital approach * Pregnancy or breastfeeding * Psychiatric or cognitive disorder precluding informed consent or follow-up

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
West China Hospital of Sichuan University Chengdu Sichuan Recruiting

More West China Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07316101 on ClinicalTrials.gov ↗ ← All trials in China